Significant ( p < 0.01 ) changes in anti-double stranded DNA antibodies , complement C3 and C4 , and reductions in B cells were observed with blisibimod.No imbalances in serious adverse events or infections ( 4/280 and 3/266 ) , deaths ( 4/280 and 3/266 ) and malignancies ( 2/280 and 2/266 ) were reported for blisibimod compared with placebo .